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A healthy lifestyle attenuates the 
effect of polypharmacy on total and 
cardiovascular mortality: a national 
prospective cohort study
David Martinez-Gomez1,3, Pilar Guallar-Castillon2,3, Sara Higueras-Fresnillo1, 
Jose R. Banegas2, Kabir P. Sadarangani4,5 & Fernando Rodriguez-Artalejo2,3
This work examines whether the increased all-cause and cardiovascular disease (CVD) mortality 
associated with polypharmacy could be offset by a healthy lifestyle. We included a prospective cohort 
of 3,925 individuals representative of the Spanish population aged ≥60 years, who were recruited 
in 2000–2001 and followed up through 2014. Polypharmacy was defined as treatment with ≥5 
medications. The following lifestyle behaviors were considered healthy: not smoking, eating a healthy 
diet, being physically active, moderate alcohol consumption, low sitting time, and adequate sleep 
duration. Individuals were classified into three lifestyle categories s: unfavorable (0–2), intermediate 
(3–4) favorable (5–6). Over a median 13.8-y follow-up, 1,822 all-cause and 675 CVD deaths occurred. 
Among individuals with polypharmacy, intermediate and favorable lifestyles were associated with 
an all-cause mortality reduction (95% confidence interval [CI]) of 47% (34–58%) and 54% (37–66%), 
respectively; 37% (9–56%) and 60% (33–76%) for CVD death, respectively. The theoretical adjusted 
hazard ratio (95%CI) associated with replacing 1 medication with 1 healthy lifestyle behavior was 0.73 
(0.66–0.81) for all-cause death and 0.69 (0.59–0.82) for CVD death. The theoretical adjusted hazard ratio 
(95%CI) for all-cause and CVD mortality associated with simply reducing 1 medication was 0.88 (0.83–
0.94) and 0.83 (0.76–0.91), respectively. Hence, adherence to a healthy lifestyle behavior can reduce 
mortality risk associated with polypharmacy in older adults.
Improvements in the effectiveness and coverage of health care, including pharmacological treatments, have 
substantially contributed to recent gains in health expectancy in old age in high-income countries1. However, 
prevention and management of age-related chronic conditions have resulted in an increased number of med-
ications taken by older adults2,3. Polypharmacy, defined as the use of multiple medications or the administra-
tion of an excessive number of medications4, is very frequent in the elderly and has been associated with many 
adverse health outcomes, including poor treatment adherence, adverse drug reactions, drug-drug interactions, 
drug-disease interactions, falls, fractures, frailty, hospitalizations, physical and cognitive functional impair-
ments, and medical errors which, in turn, increase the risk of death5. In addition, costs of drug treatments have 
risen sharply in recent decades, and represent a challenge for healthcare systems sustainability6,7. Unfortunately, 
there is little high-quality evidence to date on how to reduce polypharmacy, with deprescribing being the main 
strategy8–10.
A healthy lifestyle has been shown to improve health in older adults11,12. Several healthy lifestyle behaviors, 
including not smoking, a healthy diet, being physically active, moderate alcohol consumption, less sedentariness 
and adequate sleep duration have well-documented positive effects on mortality in the elderly; in fact, it seems 
that it is never too late to obtain some benefits from adopting healthy lifestyle behaviors13–18. Therefore, it is of 
interest to assess whether the adverse mortality effect of polypharmacy could be attenuated by a healthy lifestyle 
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in the old age. These findings might represent an important shift in the approach to provide health in among older 
adults because the objectives go beyond preventing deaths exclusively through pharmacology treatments. Hence, 
we used data from a cohort of older adults in Spain to examine whether the increased all-cause and cardiovascu-
lar disease (CVD) mortality associated with polypharmacy could be offset by a healthy lifestyle. Additionally, we 
assessed the theoretical mortality benefits that could be obtained by replacing medications with healthy lifestyle 
behaviors in individuals with polypharmacy.
Methods
Study design and participants. We analyzed data from a cohort of 4,008 individuals, representative of the 
non-institutionalized population aged ≥60 years in Spain16,19. The study participants were recruited in 2000/2001 
using probabilistic and multistage cluster sampling. The clusters were initially stratified according to region of 
residence and size of municipality. Next, census sections and households were successively chosen randomly 
within each cluster. Study participants were finally selected in sex and age strata. The final study participation 
rate was 71%. Data were collected by home-based personal interview and physical examination, performed by 
trained personnel. All methods were carried out in accordance with relevant guidelines/regulations. The study 
was approved by the Clinical Research Ethics Committee of the La Paz University Hospital in Madrid, Spain. All 
participants provided written informed consent.
Exposure variables. During the home visit, participants were asked to show all prescribed and 
over-the-counter medications that they were currently taking. We recorded up to ten medications, and the total 
number of drugs was classified into three categories: 0–1 medications, 2–4 medications and ≥5 medications or 
polypharmacy in the current study20.
We considered six lifestyle behaviors that were self-reported with standardized and validated question-
naires21–26: (i) smoking, (ii) diet, (iii) alcohol consumption, (iv) physical activity, (v) sedentary behavior and (vi) 
sleep duration. According to published evidence and lifestyle recommendations12–18, the following lifestyle behav-
iors were considered healthy: not smoking (never smoking or having quit >15 years ago), eating a healthy diet 
(index ≥median in the cohort), being physically active (very/moderately active), moderate alcohol intake (≤20 
and ≤ 30 g/d in female and male drinkers, respectively), low sedentariness (≤7 h/d), and adequate sleep duration 
(7–8 h/d). A healthy lifestyle score was defined as the number of healthy lifestyle behaviors, and individuals were 
classified into three categories: unfavorable (0–2 healthy lifestyle behaviors), intermediate (3–4 healthy lifestyle 
behaviors), and favorable (5–6 healthy lifestyle behaviors).
Ascertainment of mortality. The outcome variables were all-cause and CVD mortality from the study 
baseline through the end of follow-up at December 31, 2014. The number, cause and date of deaths were obtained 
by a computerized search of the National Death Index of the Ministry of Health and the vital registry of the 
National Institute for Statistics. The vital status was successfully ascertained for 99.9% of the cohort. The underly-
ing cause of death was determined by a nosologist according to the International Classification of Diseases, Tenth 
Edition, with cardiovascular death corresponding to codes I00-I99.
Other variables. Sex, age, and educational level were recorded. Body weight, height and waist circumference 
were measured and body mass index (BMI) was calculated as kg/m2 19. Blood pressure readings were performed 
in the right arm at the level of the heart using standardized methods27. Hypercholesterolemia was defined as an 
affirmative answer to the following question: Has your doctor ever told you that you have high (blood) choles-
terol? Cognitive function was assessed with the Mini-Mental State Examination28,29. Agility and mobility lim-
itations were defined as an affirmative answer to standardized questions30. Finally, we registered the following 
diseases diagnosed by a physician and reported by the study participant: chronic lung disease, CVD, diabetes 
mellitus, cancer at any site, and depression.
Statistical analyses. Of the 4,008 study participants, 83 were excluded because of missing data on lifestyle 
behaviors or other variables, so the final sample comprised 3,925 individuals (2,214 women). Pearson correlation 
was used to analyze the relationship between the number of medications and healthy lifestyle behaviors.
Cumulative all-cause and CVD mortality according to medication and healthy lifestyle behaviors were calcu-
lated using the Kaplan-Meier method, and differences were assessed with log-rank tests. We also used Cox pro-
portional hazards regression, with days as the time scale, to estimate the hazard ratios (HRs) and 95% confidence 
intervals (CIs) for all-cause and CVD mortality associated with medication or healthy lifestyle behaviors. The 
analyses took 0–1 medications or a favorable lifestyle, respectively, as the reference category. The dose-response 
relationship was tested with a P for trend, calculated by modeling the number of medications and healthy lifestyle 
behaviors as continuous variables; we also used restricted cubic spline regression to graphically illustrate this 
relationship.
Next, to examine whether healthy lifestyle behaviors attenuate the effect of medications on all-cause or CVD 
mortality we initially estimated the association between healthy lifestyle behaviors and mortality outcomes strat-
ified by medication categories. Also, we checked the potential modifier effect of medications on the associations 
between healthy lifestyle behaviors and mortality outcomes by including an interaction term in Cox models. 
Then, we assessed the association of the combined exposure to healthy lifestyle behaviors and medications with 
mortality by modelling nine categories of exposure (that is, 3 medication categories ×3 healthy lifestyle behaviors 
categories) and participants taking 0–1 medications with a favorable lifestyle was the reference category –hypo-
thetically the healthiest category.
Finally, the theoretical all-cause and CVD mortality benefit from reduced polypharmacy, achieved by replac-
ing 1 medication with 1 healthy lifestyle behavior, was estimated in a way similar to isotemporal/isocaloric substi-
tution models31,32 among participants taking ≥5 medications. Since these methods of analysis assume a constant 
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amount of “discretionary time or calories”, we considered that the total number of medications and healthy life-
style behaviors represented a constant amount of “discretionary options”. The theoretical mortality benefits of 
deprescribing 1 medication to reduce polypharmacy was operationalized as decreasing any medication and tested 
by reversing the order in the medication exposure variable (i.e., decreasing the number of medications taken) 
among older adults taking ≥5 medications. We also calculated a risk advancement period, which shows the 
difference in survival in persons with a varying number of medications or healthy lifestyle behaviors that is equiv-
alent to the all-cause or CVD mortality associated with each 1-year increase in chronological age16.
Analyses were first adjusted for sex and age (model 1), and subsequently for educational attainment, BMI, 
waist circumference, systolic blood pressure, hypercholesterolemia, Mini-Mental State Examination score, agility 
limitation, mobility limitation, chronic lung disease, CVD, cancer, diabetes mellitus, and depression (model 2). 
These covariates were selected according to previous works in the same research area5. Multicollinearity detection 
was examined in all analyses, but variance inflation factors were in the normal range.
We assessed the assumption of proportionality of hazards both graphically and by testing the significance of 
the interaction of medication or healthy lifestyle with time of follow-up, and we found no evidence of departure 
from such assumption (all P for interaction > 0.1). Statistical significance was set at two-sided P < 0.05. Analyses 
were performed with STATA® v.14.1 for Macintosh.
Results
Descriptive characteristics of the study participants at baseline by medication and healthy lifestyle categories are 
reported in Table 1. Overall, compared to participants with 0–1 medications or with a favorable lifestyle, those 
taking ≥5 medications or with an unfavorable lifestyle were older and more frequently women, and had lower 
education, more functional and cognitive limitations, and more chronic diseases. There was only a weak correla-
tion, albeit significant, between the number of medications and healthy lifestyle behaviors (r = −0.15, P < 0.001).
Over a median follow-up of 13.8 years (5th to 95th percentile: 1.9–14.2) a total of 1,822 deaths occurred, 675 
of them due to cardiovascular disease. In Kaplan-Meier analyses, cumulative all-cause and CVD deaths progres-
sively increased with the number of medications and decreased from unfavorable through favorable categories of 
lifestyle (all log-rank tests P < 0.001) (Figure S1).
After multivariable adjustment (model 2, Table 2), and compared to taking 0–1 medications, the adjusted HR 
(95%CI) of all-cause death was 1.32 (1.15–1.51) for 3–4 medications and 1.75 (1.49–2.06) for ≥5 medications; 
corresponding results for CVD mortality were 1.50 (1.17–1.92) and 2.11 (1.60–2.78). In contrast, those with 
intermediate and favorable vs unfavorable lifestyle had an adjusted HR (95%CI) of 0.58 (0.51–0.67) and 0.48 
(0.40–0.57) for all-cause mortality, and of 0.55 (0.43–0.70) and 0.45 (0.32–0.59) for CVD mortality (Table 2). 
Both medications and healthy lifestyles showed a clear dose-response with mortality (Figure S2); the adjusted 
HR (95%CI) for all-cause and CVD mortality associated with 1-medication increase were 1.12 (1.09–1.14) and 
1.15 (1.10–1.19), respectively, and with 1-healthy lifestyle behavior increase were 0.81 (0.77–0.85) and 0.78 (0.72–
0.85), respectively (all P for trend < 0.001) (Table 2). These associations remained virtually the same after adjust-




P0–1 2–4 ≥5 Unfavorable Intermediate Favorable
n 1295 1787 843 665 2308 952
  Women, % 48.8 58.6 63.6 <0.001 57.9 57.4 53.0 0.028
  Age, years 70.7 ± 8.0 72.0 ± 7.8 73.6 ± 7.9 <0.001 75.4 ± 8.5 71.7 ± 7.8 69.9 ± 7.0 <0.001
Educational attainment, %
  No education 48.0 51.1 59.8 64.6 52.6 41.6
  Primary 36.1 36.8 29.9 26.1 34.7 42.2
  Secondary or higher 15.9 12.1 10.3 <0.001 9.4 12.7 16.2 <0.001
Body mass index, kg/m2 28.3 ± 4.1 29.0 ± 4.5 29.6 ± 4.8 <0.001 28.9 ± 5.3 28.9 ± 4.4 28.7 ± 4.0 0.265
Waist circumference, cm 97.3 ± 11.2 98.8 ± 12.1 100.8 ± 12.5 <0.001 99.8 ± 13.9 98.5 ± 11.6 98.6 ± 11.5 0.067
Systolic blood pressure, 
mm Hg 142.3 ± 18.5 144.1 ± 18.8 142.6 ± 21.0 0.465 144.7 ± 21.0 143.3 ± 19.0 141.8 ± 18.4 0.003
Hypercholesterolemia, % 17.8 25.6 32.6 <0.001 19.4 25.0 27.1 0.001
MMSE, score 25.8 ± 4.3 25.5 ± 4.5 24.9 ± 4.5 <0.001 23.6 ± 5.4 25.5 ± 4.4 26.6 ± 3.3 <0.001
Agility limitations, % 42.5 60.5 79.8 <0.001 76.9 59.3 44.5 <0.001
Mobility limitations, % 34.7 52.2 73.9 <0.001 75.7 50.9 34.2 <0.001
Chronic lung disease, % 7.0 14.5 25.4 <0.001 19.5 15.0 9.1 <0.001
Cardiovascular disease*, % 2.1 7.6 21.1 <0.001 13.7 8.3 6.1 <0.001
Diabetes, % 4.9 15.7 30.4 <0.001 19.1 14.5 14.7 0.065
Cancer, % 1.3 1.8 2.5 0.058 2.2 1.9 1.3 0.744
Depression, % 3.4 10.7 20.1 <0.001 15.3 10.4 6.7 <0.001
Table 1. Characteristics of the participants at baseline, by categories of medication and healthy lifestyle. Values 
are means ± SD or %. MMSE: Mini-Mental State examination.
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The association between heathy lifestyle behaviors and mortality did not vary by medication category (all P 
for interactions >0.1). Among participants with polypharmacy (≥5 medications), an intermediate or favorable 
lifestyle was associated with an all-cause mortality reduction (95%CI) of 47% (34–58%) and 54% (37–66%), 
respectively; for CVD death, figures were 37% (9–56%) and 60% (33–76%) (Table 3). In combined analyses, 
adherence to a healthier lifestyle attenuated the increased all-cause and CVD mortality associated with taking 
2–4 medications and polypharmacy remarkably (Fig. 1 and Table S2). Also, as compared to participants with 0–1 
medications and a favorable lifestyle, those with ≥5 medications and an unfavorable lifestyle had the highest risk 
of all-cause death (HR = 3.70, 95%CI: 2.67–5.12) and CVD death (HR = 5.09, 95%CI: 2.84–9.10) (Fig. 1).
n
All-cause mortality HR (95%CI) CVD mortality HR (95%CI)
Cases Model 1 Model 2 Cases Model 1 Model 2
Medication category
  0–1 medications 1295 452 1 (Reference) 1 (Reference) 137 1 (Reference) 1 (Reference)
  2–4 medications 1787 842 1.38 (1.20–1.57) 1.32 (1.15–1.51) 316 1.64 (1.29–2.08) 1.50 (1.17–1.92)
  ≥5 medications 843 528 2.03 (1.75–2.34) 1.75 (1.49–2.06) 222 2.68 (2.09–3.43) 2.11 (1.60–2.78)
  P for trend <0.001 <0.001 <0.001 <0.001
  Per 1-medication 
increase 1.14 (1.11–1.16) 1.12 (1.09–1.14) 1.19 (1.15–1.23) 1.15 (1.10–1.19)
Healthy lifestyle category
  Unfavorable 665 469 1 (Reference) 1 (Reference) 195 1 (Reference) 1 (Reference)
  Intermediate 2308 1027 0.55 (0.48–0.63) 0.58 (0.51–0.67) 374 0.50 (0.40–0.63) 0.55 (0.43–0.70)
  Favorable 952 326 0.43 (0.37–0.51) 0.48 (0.40–0.57) 106 0.36 (0.27–0.48) 0.45 (0.32–0.59)
  P for trend <0.001 <0.001 <0.001 <0.001
  Per 1-healthy lifestyle 
increase 0.79 (0.75–0.82) 0.81 (0.77–0.85) 0.74 (0.68–0.80) 0.78 (0.72–0.85)
Table 2. All-cause and cardiovascular disease (CVD) mortality risk according to number of medications 
and healthy lifestyle behaviors in older adults. Model 1 adjusted for sex and age. Model 2 adjusted as in 
model 1 and for educational attainment, body mass index, waist circumference, systolic blood pressure, 
hypercholesterolemia, Mini-Mental State Examination, agility limitations, mobility limitations, chronic lung 
disease, CVD, cancer, diabetes mellitus, and depression.
n
All-cause mortality HR (95%CI) CVD mortality HR (95%CI)
Cases Model 1 Model 2 Cases Model 1 Model 2
With 0–1 medications
  Unfavorable lifestyle 147 93 1 (Reference) 1 (Reference) 43 1 (Reference) 1 (Reference)
  Intermediate lifestyle 794 267 0.63 (0.45–0.89) 0.63 (0.45–0.88) 72 0.41 (0.25–0.67) 0.42 (0.26–0.70)
  Favorable lifestyle 354 92 0.55 (0.37–0.80) 0.56 (0.38–0.83) 22 0.34 (0.18–0.63) 0.39 (0.20–0.74)
  P for trend 0.002 0.005 <0.001 0.001
  Per 1-healthy lifestyle 
increase 0.85 (0.76–0.94) 0.85 (0.76–0.95) 0.71 (0.59–0.86) 0.73 (0.60–0.89)
With 2–4 medications
  Unfavorable lifestyle 304 207 1 (Reference) 1 (Reference) 81 1 (Reference) 1 (Reference)
  Intermediate lifestyle 1031 478 0.59 (0.49–0.71) 0.62 (0.51–0.75) 175 0.57 (0.39–0.82) 0.57 (0.40–0.83)
  Favorable lifestyle 452 157 0.43 (0.34–0.54) 0.45 (0.35–0.58) 60 0.46 (0.29–0.74) 0.47 (0.30–0.75)
  P for trend <0.001 <0.001 <0.001 <0.001
  Per 1-healthy lifestyle 
increase 0.78 (0.73–0.83) 0.79 (0.74–0.85) 0.77 (0.68–0.86) 0.78 (0.69–0.88)
With ≥5 medications
  Unfavorable lifestyle 214 159 1 (Reference) 1 (Reference) 71 1 (Reference) 1 (Reference)
  Intermediate lifestyle 483 282 0.52 (0.41–0.64) 0.53 (0.42–0.66) 127 0.57 (0.41–0.80) 0.63 (0.44–0.91)
  Favorable lifestyle 146 77 0.46 (0.35–0.61) 0.46 (0.34–0.63) 24 0.36 (0.22–0.57) 0.40 (0.24–0.67)
  P for trend <0.001 <0.001 <0.001 0.002
  Per 1-healthy lifestyle 
increase 0.80 (0.74–0.87) 0.80 (0.74–0.87) 0.78 (0.69–0.88) 0.81 (0.70–0.92)
Table 3. All-cause and cardiovascular disease (CVD) mortality risk according to healthy lifestyle in older 
adults stratified by medication category in older adults. Model 1 adjusted for sex and age. Model 2 adjusted 
as in model 1 and for educational attainment, body mass index, waist circumference, systolic blood pressure, 
hypercholesterolemia, Mini-Mental State Examination, agility limitations, mobility limitations, chronic lung 
disease, CVD, cancer, diabetes mellitus, and depression.
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Among those with polypharmacy, the adjusted mortality HR (95%CI) associated with replacing 1 medication 
with 1 healthy lifestyle behavior was 0.73 (0.66–0.81) for all-cause death and 0.69 (0.59–0.82) for CVD death 
(Figure S3); it is approximately equivalent to the reduced mortality associated with being 3 years younger. This 
suggests that replacement might have greater benefits than deprescribing, because the adjusted HR (95%CI) 
for all-cause and CVD mortality associated with simply reducing 1 medication was 0.88 (0.83–0.94) and 0.83 
(0.76–0.91), respectively (both P for trend < 0.001); this is a mortality equivalent to a 1–1.5 years younger age.
Discussion
In a population-based cohort of older adults in Spain, adherence to a healthier lifestyle was linked to a reduction 
of all-cause and CVD mortality associated with polypharmacy. Specifically, among individuals with polyphar-
macy, those with a favorable lifestyle showed a 54% and 60% lower all-cause and CVD death risk, respectively, 
than those with an unfavorable lifestyle. In addition, the theoretical effect of replacing medications with healthy 
lifestyle behaviors evinced a greater reduction of mortality than simply deprescribing the number of medications. 
Since taking medications and adherence to a healthy lifestyle are not related in the old age, these findings are espe-
cially important for older adults, which usually take an excessive number of medications, and therefore, public 
health and clinical strategies are needed to improve their health behaviors.
Although many clinical trials have shown that drug treatments improve survival in different clinical sce-
narios, we found that the number of medications taken had a direct dose-response relationship with mortality 
from all causes and CVD –the leading cause of death among older adults. Individuals with ≥5 medications had 
about two times higher risk of death (HR = 1.75, 95%CI: 1.49–2.06 for all-cause mortality and HR = 2.11, 95%CI: 
1.60–2.78 for CVD mortality) than those with none or only 1 medication. Our results are in line with most previ-
ous research on this topic, regardless of the cut-point selected to define polypharmacy5. In fact, studies with better 
adjustment for the confounding effect of morbidity found a clearer association between the number of medica-
tions taken and mortality5. Polypharmacy, therefore, can be considered a “red flag” for high mortality risk in older 
adults. Consequently, the increased risks of overtreatment by too much medication is a public health message that 
should be disseminated throughout society, given the widespread tendency to self-administer over-the-counter 
medications33–36.
In our study, adherence to a healthier lifestyle partially offsets the increased mortality associated with poly-
pharmacy. Interestingly, even an intermediate lifestyle (i.e., 3–4 out of 6 healthy lifestyle behaviors) showed a 
significant reduction in the increased mortality; this, and the observed dose-response reduction of mortality with 
a higher number of healthy lifestyle behaviors, indicates that each of them “counts” for a certain benefit. In fact, 
older adults with polypharmacy who adhered to a favorable lifestyle had an excess mortality which was similar 
Figure 1. All-cause and cardiovascular disease (CVD) mortality risk across categories of medication and 
healthy lifestyle in older adults (n = 3925). Analyses were adjusted as model 2 in Table 2. Number of participants 
in each increasing category from the X-axis segment was as follows: 354 (Ref.), 452, 146, 794, 1031, 483, 147, 
304, and 214.
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or even lower to that of those with 0–1 medications and an unfavorable lifestyle for all-cause and CVD mortality, 
respectively (Fig. 1).
On the other hand, participants taking 2–4 medications also had an increased all-cause (HR = 1.32, 95%CI: 
1.15–1.51) and CVD (HR = 1.50, 95%CI: 1.17–1.92) mortality risk in our cohort. These older adults, especially 
those who take 4 medications, are at risk for polypharmacy, and to avoid its initiation, adherence to healthier 
lifestyles would be essential and is supported by our results. For example, among individuals taking 2–4 medica-
tions, those with a favorable lifestyle had a 55% and 53% lower all-cause and CVD death risk, respectively, than 
did those with an unfavorable lifestyle (Table 3); they even had a lower mortality risk than those taking none or 1 
medication and adherence to an unfavorable lifestyle (Fig. 1).
Deprescribing is the process of tapering, stopping, discontinuing, or withdrawing medications, supervised 
by a healthcare professional (e.g., general physicians, nurses, pharmacists), with the goal of reducing polyphar-
macy8,9. Although it is feasible and safe8, two recent meta-analyses on the effect of deprescribing found no con-
vincing evidence of benefits in mortality8,9. Page et al.8 reported that, in nonrandomized studies, deprescribing to 
reduce polypharmacy significantly decreased all-cause mortality (OR = 0.32, 95%CI: 0.17–0.60), but this was not 
statistically significant in randomized trials (OR = 0.82, 95%CI 0.61–1.11). Moreover, Johansson et al.9 found that 
deprescribing polypharmacy had no effect on all-cause mortality (OR = 1.02, 95%CI: 0.84–1.23). Both reviews 
also indicated that the quality of the evidence was low and that more effective strategies to reduce polypharmacy 
should be developed and assessed8,9. In our study, we examined the impact of replacing medications with healthy 
lifestyle behaviors; thus, this included the joint effect of “deprescribing drug treatments” and “prescribing a 
healthy lifestyle” as compared with only deprescribing. While we acknowledge that the effect of medical advice on 
adopting healthy lifestyle behaviors in healthcare settings could be modest37,38, our results suggest that the benefit 
of replacement could be 2 to 3 times higher than that of only deprescribing a drug treatment; for example, while 
replacing 1 medication with 1 healthy lifestyle behavior was linked to a 27% reduction of all-cause mortality, 
reducing 1 medication was associated with only a 12% reduction. Thus a healthy lifestyle is “medicine” and may 
replace other medications. However, it must be noted that these findings are theoretical because when “depre-
scribing” some considerations such as harmful effects, the stage of the disease, doses, the importance of this med-
ication at short- medium- and long-term, and individual barriers, could not be taken into account in our study.
This study has several strengths, including a large representative sample of community-dwelling older adults 
that allows for certain generalization of results. Also, study variables were collected by trained staff using stand-
ardized methods. Moreover, analyses were adjusted for a substantial number of confounders, including chronic 
morbidity. Despite these strengths, our findings should be interpreted in the context of the following method-
ological limitations. First, since this is an observational study, there might be some residual confounding, and 
associations may not imply causation. However, the strength and dose-response of the associations found, the 
consistency across medication categories, and a long follow-up -which makes reverse causality less likely- all lend 
credence to our study results and support causal inference. Second, information on drug treatments and lifestyle 
behaviors was obtained at baseline. Our analyses assumed that medication exposure and lifestyle behaviors have 
certain stability over time, but some changes are still possible and would likely shift the observed associations 
toward the null. Third, lifestyle behaviors were self-reported and dichotomized, which may have led to recall bias 
and non-differential misclassification; again, this could have underestimated the impact of polypharmacy and 
lifestyle on mortality. Fourth, although the analyses were adjusted for several confounding variables, some poten-
tial confounders were not included due to they were not available in our study (e.g., dietary patterns, family health 
history, blood samples). In addition, we calculated a propensity score in post hoc analyses with our 12 covariates, 
which have been suggested as a potential confounder in pharmacoepidemiology39, and the associations between 
polypharmacy and mortality did no change.
In conclusion, adherence to a healthy lifestyle may help to reduce the increased risk of all-cause and CVD 
death associated with polypharmacy in older adults. In addition, replacing medications with healthy lifestyle 
behaviors may be theoretically a useful strategy to reduce polypharmacy and maximize health benefits, as com-
pared to only deprescribing. However, this strategy should be directly tested in clinical trials which, in addition 
to mortality, focus on other outcomes relevant for older people, such as frailty, falls, and cognitive and physical 
decline.
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